Good Chemistry? Beckman Will Acquire Olympus Diagnostics For $800 Mil.
This article was originally published in The Gray Sheet
Executive Summary
Beckman Coulter's proposed $800 million acquisition of Tokyo-based Olympus Diagnostics would help grow its chemistry diagnostics portfolio and expand its global presence, the firm said Feb. 27
You may also be interested in...
Beckman CEO Resigns As Company Faces Regulatory Challenges
Beckman Coulter announced the resignation of Scott Garrett as chairman, president and CEO Sept. 7 as the firm tries to recover from a recent FDA-triggered diagnostic test market withdrawal and ongoing regulatory scrutiny
Beckman CEO Resigns As Company Faces Regulatory Challenges
Beckman Coulter announced the resignation of Scott Garrett as chairman, president and CEO Sept. 7 as the firm tries to recover from a recent FDA-triggered diagnostic test market withdrawal and ongoing regulatory scrutiny
Research In Brief
CT angiography: Computerized tomographic angiography (CTA) is a safe and effective diagnostic method for ruling out serious cardiovascular disease in patients who come to an emergency department with chest pains, according to the lead author of a long-term study of CTA screening presented May 15 at the Society for Academic Emergency Medicine's annual conference in New Orleans. In the study, led by Judd Hollander, University of Pennsylvania, 481 patients who had no evidence of coronary blockage in a CTA scan were followed for one year. None of the patients had a heart attack or required a coronary revascularization procedure during the follow-up, although 11% were rehospitalized for further cardiac testing. "The ability to rapidly determine that there is nothing seriously wrong allows us to provide reassurance to the patient and to help reduce crowding in the emergency department," Hollander said. According to the Medical Imaging & Technology Alliance, previous research has shown that CTA screening saves $2,500 per patient versus admitting the patient to the hospital for more extensive testing. In a MITA press release, Hollander says: "The evidence now clearly shows that when used in appropriate patients in the emergency department, we can safely and rapidly reduce hospital admission and save money.